期刊论文详细信息
Molecular Pain
Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status
Andrea G Hohmann1  Jim Wager-Miller2  Baochang Fan2  Liting Deng1  Josée Guindon1 
[1] Program in Neuroscience, Indiana University, Bloomington, IN, USA;Department of Psychological and Brain Sciences, Gill Center for Biomolecular Science, Indiana University, 1101 E. 10th St, Bloomington, IN 47405-2204, USA
关键词: Interleukins (IL-6, IL-1β, IL-10, TNF-α);    Ibuprofen;    Morphine;    Resveratrol;    Vitamin C;    NaHCO3 (sodium bicarbonate);    Creatinine;    Neuropathic pain;    Cisplatin;    Chemotherapy;   
Others  :  1138499
DOI  :  10.1186/1744-8069-10-56
 received in 2014-03-21, accepted in 2014-08-26,  发布年份 2014
PDF
【 摘 要 】

Background

Cisplatin, a platinum-derived chemotherapeutic agent, produces antineoplastic effects coupled with toxic neuropathic pain and impaired general health status. These side-effects complicate long term studies of neuropathy or analgesic interventions in animals. We recently demonstrated that pretreatment with sodium bicarbonate (4% NaHCO3) prior to cisplatin (3 mg/kg i.p. weekly up to 5 weeks) was associated with improved health status (i.e. normal weight gain, body temperature, creatinine and ketone levels, and kidney weight ratio) in rats (Neurosci Lett 544:41-46, 2013). To reduce the nephrotoxic effects of cisplatin treatment in mice, we compared effects of sodium bicarbonate (4% NaHCO3 s.c.), vitamin C (25 mg/kg s.c.), resveratrol (25 mg/kg s.c.) and saline (0.9% NaCl) pretreatment on cisplatin-induced changes in animal health status, neuropathic pain and proinflammatory cytokine levels in spinal cord and kidney.

Results

Cisplatin-treated mice receiving saline pretreatment exhibited elevated ketone, creatinine and kidney weight ratios, representative of nephrotoxicity. Vitamin C and sodium bicarbonate lowered creatinine/ketone levels and kidney weight ratio whereas resveratrol normalized creatinine levels and kidney weight ratios similar to saline pretreatment. All pretreatments were associated with decreased ketone levels compared to saline pretreatment. Cisplatin-induced neuropathy (i.e. mechanical and cold allodynia) developed equivalently in all pretreatment groups and was similarly reversed by either morphine (6 mg/kg i.p.) or ibuprofen (6 mg/kg i.p.) treatment. RT-PCR showed that mRNA levels for IL-1β were increased in lumbar spinal cord of cisplatin-treated groups pretreated with either saline, NaHCO3 or resveratrol/cisplatin-treated groups. However, IL-6 and TNF-alpha were elevated in the kidneys in all cisplatin-treated groups. Our studies also demonstrate that 60 days after the last cisplatin treatment, body weight, body temperature, kidney functions and mRNA levels have returned to baseline although the neuropathic pain (mechanical and cold) is maintained.

Conclusions

Studies employing cisplatin should include NaHCO3 or vitamin C pretreatment to improve animal health status and reduce nephrotoxicity (lower creatinine and kidney weight ratio) without affecting the development of chemotherapy-induced neuropathy or analgesic efficacy.

【 授权许可】

   
2014 Guindon et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150320042408136.pdf 1713KB PDF download
Figure 7. 87KB Image download
Figure 6. 138KB Image download
Figure 5. 97KB Image download
Figure 4. 108KB Image download
Figure 3. 163KB Image download
Figure 2. 106KB Image download
Figure 1. 101KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Perry MC: Companion Handbook to the Chemotherapy Sourcebook. Baltimore: Williams & Wilkins; 1999.
  • [2]Pfister DG, Sum YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006, 24:1072-1078.
  • [3]Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS: Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012, 32:7091-7101.
  • [4]Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S: Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012, 8:55. BioMed Central Full Text
  • [5]Verdú E, Vilches JJ, Rodríguez FJ, Ceballos D, Valero A, Navarro X: Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999, 22:329-340.
  • [6]Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F: An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003, 182:12-20.
  • [7]Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R: WIN 55,212–2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007, 81:468-479.
  • [8]Guindon J, Hohmann AG: Use of sodium bicarbonate to promote weight gain, maintain body temperature, normalize renal functions and minimize mortality in rodents receiving the chemotherapeutic agent cisplatin. Neurosci Lett 2013, 544:41-46.
  • [9]Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ: Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010, 6:15. BioMed Central Full Text
  • [10]Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ: A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One 2013, 8:e54161.
  • [11]Alberts DS, Noel JK: Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995, 6:369-383.
  • [12]Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9-17.
  • [13]Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci 2007, 334:115-124.
  • [14]Apfel SC, Arezzo JC, Lipson L, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31:76-80.
  • [15]Authier N, Fialip J, Eschalier A, Coudoré F: Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett 2000, 291:73-76.
  • [16]Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A: Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6:620-629.
  • [17]Cata JP, Weng HR, Dougherty PM: Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res 2008, 1230:91-98.
  • [18]Bacci G, Ferrari S, Longhi A, Forni C, Loro L, Beghelli C, Tremosini M, Versari M: Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003, 10:851-857.
  • [19]Mir O, Ropert S, Babinet A, Alexandre J, Larousserie F, Durand JP, Enkaoua E, Anract P, Goldwasser F: Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 2010, 66:1059-1063.
  • [20]Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM, Bianchi , Mde L: Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 2008, 82:363-370.
  • [21]Appenroth D, Fröb S, Kersten L, Splinter FK, Winnefeld K: Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997, 71:677-683.
  • [22]Antunes LM, Darin JD, Bianchi MD: Protective effects of vitamin c against cisplatin- induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 2000, 41:405-411.
  • [23]Behling EB, Sendão MC, Francescato HD, Antunes LM, Costa RS, Bianchi Mde L: Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol Rep 2006, 58:526-532.
  • [24]Vera G, Chiarlone A, Martín MI, Abalo R: Altered feeding behaviour induced by long- term cisplatin in rats. Auton Neurosci 2006, 126–127:81-92.
  • [25]Bhattacharyya S, Mehta P: The hepatoprotective potential of Spirulina and vitamin C supplemention in cisplatin toxicity. Food Funct 2012, 3:164-169.
  • [26]Oishi K, Hagiwara S, Koga S, Kawabe S, Uno T, Iwasaka H, Noguchi T: The vitamin E derivative, EPC-K1, suppresses inflammation during hepatic ischemia-reperfusion injury and exerts hepatoprotective effects in rats. J Surg Res 2012, 176:164-170.
  • [27]Hillyer EV, Quesenberry KE: Ferrets, rabbits and rodents; clinical medicine and surgery. 1st edition. New York: Elsevier Health Science; 1996.
  • [28]Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG: Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 2013, 67:94-109.
  • [29]Stratton JA, Braly PS, DiSaia PJ: Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen. Gynecol Oncol 1984, 18:145-149.
  • [30]Duffy CP, Elliott CJ, O’Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O’Loughlin CM, NicAmhlaoibh R, Clynes M: Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non- steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998, 34:1250-1259.
  • [31]Roller A, Bähr OR, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M: Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 1999, 259:600-605.
  • [32]Keppler A, Gretz N, Schmidt R, Kloetzer HM, Groene HJ, Lelongt B, Meyer M, Sadick M, Pill J: Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int 2007, 71:74-78.
  • [33]Askew EW, Dohm GL, Huston RL: Fatty acid and ketone body metabolism in the rat: response to diet and exercise. J Nutri 1975, 105:1422-1432.
  • [34]Koch DD, Feldbruegge DH: Optimized kinetic method for automated determination of beta-hydroxybutyrate. Clin Chem 1987, 33:1761-1766.
  • [35]Callaghan BC, Little AA, Feldman EL, Hughes RA: Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012, 6:CD007543.
  • [36]Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007, 322:8-15.
  • [37]Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebulla P, Introna M, Capelli C, Benigni A, Remuzzi G, Lazzari L: Life-sparing effect of human cord blood- mesenchymal stem cells in experimental acute kidney injury. Stem Cells 2010, 28:513-522.
  • [38]Reers S, Pfannerstill AC, Rades D, Maushagen R, Andratschke M, Pries R, Wollenberg B: Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res 2013, 33:2481-2489.
  • [39]Sugama S, Takenouchi T, Sekiyama K, Kitani H, Hashimoto M: Immunological responses of astroglia in the rat brain under acute stress: interleukin 1 beta co- localized in astroglia. Neuroscience 2011, 192:429-437.
  • [40]Dong Y, Wang S, Zhang T, Zhao X, Liu X, Cao L, Chi Z: Ascorbic acid ameliorates seizures and brain damage in rats through inhibiting autophagy. Brain Res 2013, 1535:115-123.
  • [41]Zamani M, Soleimani M, Golab F, Mohamadzadeh F, Mehdizadeh M, Katebi M: NeuroProtective effects of adenosine receptor agonist coadministration with ascorbic acid on CA1 hippocampus in a mouse model of ischemia reperfusion injury. Metab Brain Dis 2013, 28:367-374.
  • [42]Chang WW, Liu JJ, Liu CF, Liu WS, Lim YP, Cheng YJ, Lee CH: An extract of Rhodobacter sphaeroides reduces cisplatin-induced nephrotoxicity in mice. Toxins (Basel) 2013, 5:2353-2365.
  • [43]Kodama A, Watanabe H, Tanaka R, Kondo M, Chuang VT, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M, Maruyama T: Albumin fusion renders thioredoxin an effective anti- oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. Biochim Biophys Acta 1840, 2014:1152-1162.
  • [44]Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
  • [45]Genedani S, Bernardi M, Bertolini A: Influence of antineoplastic drugs on morphine analgesia and on morphine tolerance. Eur J Pharmacol 1999, 367:13-17.
  • [46]Guindon J, De Léan A, Beaulieu P: Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 2006, 121:85-93.
  • [47]Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG: Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal. Biol Psychiatry 2014. doi: 10.1016/j.biopsych.2014.04.009
  • [48]Ward SJ, Ramirez MD, Neelakantan H, Walker EA: Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. Anesth Analg 2011, 113:947-950.
  • [49]Draper NR, Smith H: Applied regression analysis. New York: Wiley; 1998.
  文献评价指标  
  下载次数:142次 浏览次数:10次